This research document defines 'disease stability' as a new therapeutic indicator for chronic obstructive pulmonary disease (COPD) and verifies its clinical significance. Stability is presented as an ...

Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive pulmonary disease (COPD), yet fatigue often persists despite rehabilitation. We ...

Persistent access barriers leave many treatment candidates without advanced therapy as physicians look for stronger disease ...

Precision medicine approaches for chronic obstructive pulmonary disease (COPD) are lagging, creating gaps in care and leaving ...

An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market ...

Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, ...

Advancements in COPD treatment are offering relief to thousands of Kentuckians by targeting inflammation directly without the ...

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales ...

A new drug shows promise in reducing the symptoms of COPD, one of the top 10 leading cause of death in the U.S., according to ...

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that ...

AstraZeneca’s experimental COPD drug has significantly reduced flare-ups in two late-stage trials, making FDA approval in ...

A new drug appeared to show promise in reducing rates of chronic obstructive pulmonary disease (COPD) symptoms in former and current smokers, according to results from late-stage clinical trials.